Sanofi

Clinical Study Results Medicines, including Rare Diseases

Important

Information about sponsored clinical trials and result information are provided for informational purposes only and are not intended to promote any product or use. Clinical study results are intended to report the results of the study that were known at the time of the study's completion. The results therefore do not provide a comprehensive and current review of the safety and efficacy of any drug based upon all information available. Physicians and patients should refer to the current approved product labeling for information on approved indications in their country. In the event that the product is described as no longer a Sanofi product, reasons could include that the product was transferred to another company.

This information is not intended to replace the advice of a health care professional. Only a physician can determine if a specific medicine is the correct or best treatment option for a particular patient. If you have questions, please consult a health care professional.

Filter by:

And

1248 result(s) found
Generic NameTrade NameCondition(s)Study CodeStudy NameAccess to Study / ProtocolAccess to Results
ALIROCUMAB
Praluent
Hypercholesterolemia
LTS11717ODYSSEY LONG TERMNCT01507831Tabulated Results
ALIROCUMAB
Praluent
Hypercholesterolemia
LTS13463ODYSSEY OLEEudraCT: 2013-002572-40Tabulated Results
ALIROCUMAB
Praluent
Hypercholesterolemia
MSC14864NANCT03415178Tabulated Results
ALIROCUMAB
Praluent
Hypercholesterolemia
POP12671NANCT01670734Summary
ALOGLIPTIN
Nesina
Diabetes Mellitus, Type 2
ALOGLC08867ACADEMICNCT03794336Publication reference
ALOMFILIMAB
Not marketed
Squamous Cell Carcinoma of Head and Neck; Non-small Cell Lung Cancer; Hepatocellular Carcinoma; Esophageal Cancer; Gastric Cancer; Melanoma; Renal Cell Carcinoma; Pancreatic Cancer; Cervical Cancer; Triple Negative Breast Cancer; Advanced Cancer; Metastatic Cancer
TCD17370NANCT03829501Tabulated Results
AMBROXOL
Not marketed
Acute Pharyngitis
LPS15328DELICIOUSNCT03583658Summary
AMCENESTRANT
Not marketed
Breast Cancer metastatic
ACT16105AMEERA-3NCT04059484Tabulated Results
AMCENESTRANT
Not marketed
Breast Cancer
ACT16106AMEERA-4NCT04191382Tabulated Results
AMCENESTRANT
Not marketed
Breast Cancer
BEX15859NANCT04940026Summary

References:

* These study results were previously posted on GenzymeClinicalResearch.com
** This link replaces the same summary that was previously posted